ABclonal Biotechnology, a Woburn, Mass.-based global life science tools and services provider, completed its $92.9m Series C financing.
The round was led by Sequoia Capital China and LYFE Capital, with participation from Sigma Square Capital, Kinghall Ventures, and Lucion Capital.
Led by Zack Wu, CEO, ABclonal Biotechnology is the parent company of ABclonal Technology, a Massachusetts-based life science research and diagnostic reagents manufacturer,
The company intends to use the funds to accelerate its research and development pipeline for in vitro diagnostic raw materials and expand production capabilities of its research reagent products and services. It is also currently in talks to acquire a contract research organization focused on single-cell-based monoclonal antibody development.